Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics.

Autor:	Kosiborod MN; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri, USA. Electronic address: mkosiborod@saint-lukes.org., Cherney D; University Health Network and Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada., Connelly K; St. Michael's Hospital, Toronto, Ontario, Canada., Desai AS; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: https://twitter.com/akshaydesaimd., Guimarães PO; Cardiovascular Clinical Trials Academic Research Organization, Hospital Albert Einstein, São Paulo, Brazil., Kuthi L; Semmelweis University, Budapest, Hungary., Lala A; The Mount Sinai Hospital, New York, New York, USA., Madrini V Jr; Hospital Israelita Albert Einstein, São Paulo, Brazil., Merkely B; Semmelweis Egyetem, Budapest, Hungary., Villota JN; Hospital Clinico Universitario de Valencia, Valencia, Spain., Squire I; University Hospitals of Leicester NHS Trust - Glenfield Hospital, Leicester, United Kingdom., Testani JM; Section of Cardiovascular Medicine, Yale University, Guilford, Connecticut, USA., Vaclavik J; University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic., Verma S; Institute of Unity Health Toronto and University of Toronto, Toronto, Ontario, Canada., Wranicz J; Department of Electrocardiology, Medical University of Lodz, Łódź, Poland., Dahl M; BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden., Eudicone JM; BioPharmaceuticals Medical (Evidence), AstraZeneca, Wilmington, Delaware, USA., Friberg L; BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden., Petrie MC; Institute of Cardiovascular and Medical Sciences, University of Glasgow, and Glasgow Royal Infirmary, Glasgow, United Kingdom. Electronic address: https://twitter.com/markcpetrie20.
Jazyk:	angličtina
Zdroj:	JACC. Heart failure [JACC Heart Fail] 2024 Oct; Vol. 12 (10), pp. 1707-1716. Date of Electronic Publication: 2024 May 13.
DOI:	10.1016/j.jchf.2024.05.003
Abstrakt:	Background: Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF). However, MRAs are often underused because of hyperkalemia concerns. Objectives: The purpose of this study was to assess whether sodium zirconium cyclosilicate (SZC), a nonabsorbed crystal that traps and rapidly lowers potassium, enables MRA use in patients with HFrEF and prevalent hyperkalemia (or at high risk). Methods: REALIZE-K is a prospective, double-blind, placebo-controlled trial in patients with HFrEF (NYHA functional class II-IV; left ventricular ejection fraction ≤40%), optimal therapy (except MRA), and prevalent hyperkalemia (or at high risk). During the open-label run-in, all participants underwent protocol-mandated spironolactone titration (target: 50 mg daily); those with prevalent (cohort 1) or incident (cohort 2) hyperkalemia during titration started SZC. Participants achieving normokalemia while on spironolactone ≥25 mg daily were randomized to continuing SZC or matching placebo for 6 months. The primary composite endpoint was proportion of participants with optimal response (normokalemia, on spironolactone ≥25 mg daily, no rescue for hyperkalemia [months 1-6]). Results: Of 365 patients (run-in), 202 were randomized. Baseline characteristics included mean age 70 years, prevalent comorbidities (78% estimated glomerular filtration rate <60 mL/min/1.73 m 2 , 38% atrial fibrillation/flutter), high N-terminal pro B-type natriuretic peptide (median 1,136 pg/mL), and high HFrEF therapy use (64% sacubitril/valsartan, 96% beta-blocker, 42% sodium glucose co-transporter 2 inhibitor). At randomization, 78% were receiving spironolactone 50 mg daily. Conclusions: REALIZE-K is the first trial to evaluate whether SZC can enable rapid and safe MRA optimization and long-term continuation in patients with HFrEF and prevalent/high risk of hyperkalemia. (Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients with Symptomatic HFrEF Receiving Spironolactone [REALIZE-K]; NCT04676646). Competing Interests: Funding Support and Author Disclosures The REALIZE-K trial was funded by AstraZeneca. Drs Kosiborod, Cherney, Connelly, Desai, Guimarães, Kuthi, Lala, Madrini, Merkely, Villota, Squire, Testani, Vaclavik, Verma, Wranicz, and Petrie have received research funding in the form of grants to institutions from AstraZeneca and/or consulting for AstraZeneca. Mr Dahl, Mr Eudicone, and Ms Friberg are employees of, and hold or may hold stock in, AstraZeneca. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu